Company filings profile · CIK 0001157075
PharmaCyte Biotech, Inc. — SEC filings & insider activity.
Real, source-linked SEC EDGAR activity for PharmaCyte Biotech, Inc. (PMCB): 5 filings in the last 90 days vs 12 in the prior 90 (filing-velocity cooling ↓ · 0.42×). Latest material 8-K events, insider Form-4 transactions, and periodic reports — monitored for change.
✔ Verified against the public SEC EDGAR filing record as of Aug 5, 2026. Source-linked, daily-refreshed.
Material 8-K events — PharmaCyte Biotech, Inc.
8-K disclosures decoded by item code (the material events: agreements, results, control/management changes, impairments, restatements).
| Filed | Event | |
|---|---|---|
| Apr 2, 2026 | Departure/Election of Directors or Officers; Item 5.07; Financial Statements and Exhibits | ↗ |
| Dec 5, 2025 | Delisting / Listing-Rule Failure | ↗ |
| Oct 31, 2025 | Departure/Election of Directors or Officers; Item 5.07; Financial Statements and Exhibits | ↗ |
| Sep 5, 2025 | Entry into a Material Agreement; Completion of Acquisition/Disposition; Regulation FD Disclosure; Financial Statements and Exhibits | ↗ |
Watch PharmaCyte Biotech, Inc. automatically
Add this company to a watchlist and get a webhook/email the moment it files a material 8-K, an insider Form 4, or changes its risk-factor language.
Recent filings
| Filed | Form | Detail | |
|---|---|---|---|
| Jul 29, 2026 | 10-K | FORM 10-K FOR APRIL 2026 | ↗ |
| Jul 17, 2026 | 4/A | ↗ | |
| Jul 17, 2026 | 4/A | ↗ | |
| Jul 17, 2026 | 4/A | ↗ | |
| Jul 17, 2026 | 4/A | ↗ | |
| Apr 2, 2026 | 4 | ↗ | |
| Apr 2, 2026 | 4 | ↗ | |
| Apr 2, 2026 | 4 | ↗ | |
| Apr 2, 2026 | 4 | ↗ | |
| Apr 2, 2026 | 8-K | Departure/Election of Directors or Officers; Item 5.07; Financial Statements and Exhibits | ↗ |
| Mar 18, 2026 | 4 | ↗ | |
| Mar 18, 2026 | SCHEDULE 13G | ↗ | |
| Mar 17, 2026 | 10-Q | FORM 10-Q FOR JAN 2026 | ↗ |
| Mar 9, 2026 | ARS | ANNUAL REPORT | ↗ |
| Mar 9, 2026 | DEF 14A | DEFINITIVE PROXY STATEMENT | ↗ |
| Feb 27, 2026 | PRE 14A | PRELIMINARY PROXY STATEMENT | ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A | ↗ | |
| Jan 7, 2026 | 4 | ↗ | |
| Jan 7, 2026 | 4 | ↗ | |
| Dec 18, 2025 | 10-Q | FORM 10-Q FOR OCT 2025 | ↗ |
| Dec 15, 2025 | NT 10-Q | EXTENSION | ↗ |
| Dec 12, 2025 | 4 | ↗ | |
| Dec 12, 2025 | 4 | ↗ | |
| Dec 12, 2025 | 4 | ↗ | |
| Dec 12, 2025 | 4 | ↗ | |
| Dec 12, 2025 | 4 | ↗ | |
| Dec 5, 2025 | 8-K | Delisting / Listing-Rule Failure | ↗ |
| Nov 18, 2025 | 4 | ↗ | |
| Nov 18, 2025 | SCHEDULE 13D/A | ↗ | |
| Nov 18, 2025 | 8-K/A | Financial Statements and Exhibits | ↗ |
| Nov 7, 2025 | SCHEDULE 13G/A | ↗ | |
| Oct 31, 2025 | 8-K | Departure/Election of Directors or Officers; Item 5.07; Financial Statements and Exhibits | ↗ |
| Oct 6, 2025 | DEF 14A | DEFINITIVE PROXY STATEMENT | ↗ |
| Sep 26, 2025 | EFFECT | Item ; Item ; Item | ↗ |
| Sep 24, 2025 | PRE 14A | PRELIMINARY PROXY STATEMENT | ↗ |
| Sep 24, 2025 | CORRESP | ↗ | |
| Sep 23, 2025 | UPLOAD | ↗ | |
| Sep 17, 2025 | S-3 | FORM S-3 | ↗ |
| Sep 15, 2025 | 10-Q | FORM 10-Q FOR JUL 2025 | ↗ |
| Sep 5, 2025 | 8-K | Entry into a Material Agreement; Completion of Acquisition/Disposition; Regulation FD Disclosure; Financial Statements and Exhibits | ↗ |